Our latest articles
Biotech smells the coffee
A couple of small M&A deals this week shows more developers capitulating to the new reality.
Sarepta loses its Momentum
A clinical hold for the company’s Exondys 51 follow-on adds further pressure on the forthcoming gene therapy readouts.
Karuna seeks a novel schizophrenia mechanism
Pivotal data will show whether KarXT can walk the risk-benefit tightrope.
To buy or build blockbusters?
A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Galapagos starts spending Gilead’s cash
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
PTC’s confirmatory Duchenne data resurrect US hopes
Real world data on Translarna look good but with a failed confirmatory trial and a troubled history, US approval is far from guaranteed.
Up-and-down test sales and a bigger Medtronic: medtech in 2028
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
The mystery of Jemperli’s rectal cancer breakthrough
If Jemperli might effectively cure a biomarker-defined subset of rectal cancer patients why isn't pharma more interested?
Cytokinetics aims to become the Vertex of cardiovascular disease
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
To back, or back away from, digital health?
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.
